Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butorphanol is a synthetic opioid analgesic classified as an opioid agonist-antagonist. It is primarily used to manage moderate to severe pain in humans and animals. Butorphanol acts as a partial agonist at the mu-opioid receptor and a full agonist at the kappa-opioid receptor, resulting in analgesia by altering pain perception within the central nervous system. Its unique pharmacological profile allows it to provide pain relief while also antagonizing some effects of pure mu-opioid agonists like morphine. Butorphanol is available in several formulations including nasal spray and injectable solutions; it can be administered intravenously, intramuscularly, or via nasal spray. In addition to its use for general pain management, it may be used during labor or surgery and has veterinary applications as an analgesic and antitussive[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butorphanol.